Haleon plc Discloses Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 17, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, disclosure, foreign-private-issuer
TL;DR
Haleon bought/sold its own shares on 9/17/25. Filing details out.
AI Summary
Haleon plc announced on September 17, 2025, that it has completed a transaction involving its own shares. The filing, a Form 6-K, details this transaction as part of its reporting for September 2025. This action is a routine disclosure for foreign private issuers.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which can be a signal to investors about the company's financial strategies or confidence.
Risk Assessment
Risk Level: low — This is a routine disclosure of a share transaction, not indicative of immediate financial distress or significant positive news.
Key Players & Entities
- Haleon plc (company) — Registrant
- September 17, 2025 (date) — Date of transaction and filing
- 001-41411 (other) — Commission File Number
FAQ
What type of transaction did Haleon plc engage in regarding its own shares?
Haleon plc completed a 'Transaction in Own Shares' as detailed in Exhibit 99.1 of the filing.
When was this transaction in own shares reported?
The transaction was reported on September 17, 2025, as part of the Form 6-K filing for the month of September 2025.
What is the purpose of a Form 6-K filing?
A Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the company has made or is required to make public in its home country.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Does Haleon plc file annual reports under Form 20-F or Form 40-F?
Haleon plc files annual reports under cover of Form 20-F, as indicated by the checkmark in the filing.
Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-17 06:48:13
Filing Documents
- a5935z.htm (6-K) — 34KB
- a5935z000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010841.txt ( ) — 39KB
From the Filing
IN OWN SHARES a5935z UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒      Form 40-F ☐                         EXHIBIT INDEX   Exhibit Number Description 99.1 17 September 2025 - “Transaction in Own Shares”     99.1     Haleon plc:   Transaction in own shares   17 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 5,357,044 ordinary shares of £0.01 each in the Company (the "Shares")   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 16 September 2025 16 September 2025 16 September 2025 Number of Shares purchased: 3,075,121 2,281,923 - Highest price paid per Share (p): 350.3000 345.0000 - Lowest price paid per Share (p): 340.9000 340.9000 - Volume weighted average price paid per Share (p): 343.8060 342.7280 -   The Company intends to hold the purchased shares as treasury shares.   Following the settlement of the above, the Company's registered share capital   is 8,952,353,648 ordinary shares of £0.01 each, of which 9,359,005 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,942,994,643 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/5932Z_1-2025-9-16.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .          SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 17, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary